THE USE OF THE SCOUT DEVICE IN EVALUATION OF DISBETES RISK IN WOMEN WITH PCOS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 多囊卵巢综合征（PCOS）是一种常见的疾病，影响6-10%的育龄妇女。与年龄和BMI匹配的女性相比，患有PCOS的女性患糖尿病前期和2型糖尿病（DM 2）的风险显著较高。糖尿病前期和DM 2在这一人群中经常被诊断不足。 患有多囊卵巢综合征的妇女经常向产科医生/妇科医生或初级保健提供者寻求医疗建议，他们可能不会要求额外的测试来评估他们的糖尿病风险。该方案探讨了使用无创性糖尿病筛查设备（SCOUT）来评估PCOS女性和年龄和BMI匹配的对照人群的糖尿病风险。SCOUT非侵入性测量由于晚期糖基化终产物（AGE）的存在而引起的皮肤荧光。已知AGEs在糖尿病前期和糖尿病患者中升高，与多囊卵巢综合征（PCOS）妇女一样威尔斯。 该方法将与用于评估前驱糖尿病和糖尿病的口服葡萄糖耐量试验（OGTT）的金标准方法进行比较。除了其他糖尿病风险评估方法（空腹血糖，HbA 1c）外，还将与OGTT进行比较，计算灵敏度和特异性。血压、胆固醇水平、糖尿病和心血管风险的血液标志物也将被测量。将纳入评估患者对糖尿病风险评估偏好的问卷。最后，皮肤荧光提供的风险评分将与PCOS中的其他代谢和激素异常（肥胖增加、高雄激素血症、高胰岛素血症、低脂联素血症）相关。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Polycystic ovary syndrome (PCOS) is a common disorder affecting 6-10% of women reproductive age. Women with PCOS are at significantly higher risk of developing prediabetes and type 2 diabetes (DM2) compared to age- and BMI-matched women. Pre-diabetes and DM2 are frequently underdiagnosed in this population. Women with PCOS often seek medical advice from their obstetrician/gynecologists or primary care providers who may not order additional tests to evaluate their diabetes risk. This protocol explores the use of a noninvasive investigational diabetes screening device (SCOUT) to evaluate diabetes risk in women with PCOS and an age and BMI-matched control population. The SCOUT noninvasively measures skin fluorescence due to the presence of advanced glycation end products (AGE). AGEs are known to be elevated in people with prediabetes and diabetes, as wells as in women with PCOS. This method will be compared to the gold standard method of an oral glucose tolerance test (OGTT) used to evaluate for prediabetes and diabetes. Sensitivity and specificity will be calculated in comparison to the OGTT in addition to other methods of diabetes risk assessment (fasting plasma glucose, HbA1c). Blood pressure, cholesterol levels, and blood markers of diabetes and cardiovascular risk will also be measured. Questionnaires to evaluate patient¿s preference of diabetes risk assessment will be included. Finally, the risk score provided by skin fluorescence will be corrrelated with other metabolic and hormonal abnormalitities in PCOS (increased adiposity, hyperandrogenemia, hyperinsulinemia, hypoadiponectinemia).